Article Versions Notes

Stevens AM, Schafer ES, Li M, Terrell M, Rashid R, Paek H, Bernhardt MB, Weisnicht A, Smith WT, Keogh NJ, et al. Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated. Cancers. 2023; 15(4):1344. https://doi.org/10.3390/cancers15041344

Stevens, Alexandra McLean, Eric S. Schafer, Minhua Li, Maci Terrell, Raushan Rashid, Hana Paek, Melanie B. Bernhardt, Allison Weisnicht, Wesley T. Smith, Noah J. Keogh, and et al. 2023. "Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated" Cancers 15, no. 4: 1344. https://doi.org/10.3390/cancers15041344

Stevens, A. M., Schafer, E. S., Li, M., Terrell, M., Rashid, R., Paek, H., Bernhardt, M. B., Weisnicht, A., Smith, W. T., Keogh, N. J., Alozie, M. C., Oviedo, H. H., Gonzalez, A. K., Ilangovan, T., Mangubat-Medina, A., Wang, H., Jo, E., Rabik, C. A., Bocchini, C., ... Redell, M. S. (2023). Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated. Cancers, 15(4), 1344. https://doi.org/10.3390/cancers15041344